Abstracts tagged "infliximab and rheumatoid arthritis (RA)"

Abstract Number: 2522 • 2014 ACR/ARHP Annual Meeting
Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations
Alejandro Balsa¹, Chamaida Plasencia-Rodriguez², Maria Gema Bonilla³, Alejandro Villalba², Diana Peiteado², Sara Garcia-Carazo⁴, Laura Nuño⁵, Teresa Jurado⁶, Emilio Martín-Mola⁷ and Dora Pascual-Salcedo⁸, ¹Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain, ²Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ³Rheumatology Unit, La Paz University Hospital, Madrid, Spain, ⁴Rheumatology, Hospital La Paz-Idipaz, Madrid, Spain, ⁵Hospital La Paz-IdiPaz, Madrid, Spain, ⁶Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁸Immunology, La Paz University Hospital, Madrid, Spain
Background/Purpose To evaluate the effects of infliximab (Ifx) dose increase in active rheumatoid arthritis (RA) patients, presenting different serum infliximab concentrations.Methods Retrospective study including 42…
Abstract Number: 2513 • 2014 ACR/ARHP Annual Meeting
The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
Chamaida Plasencia-Rodriguez¹, Dora Pascual-Salcedo², Maria Gema Bonilla³, Alejandro Villalba¹, Diana Peiteado¹, Laura Nuño⁴, Pilar Aguado⁵, Teresa Jurado⁶, Emilio Martín-Mola⁷ and Alejandro Balsa⁸, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Immunology, La Paz University Hospital, Madrid, Spain, ³Rheumatology Unit, La Paz University Hospital, Madrid, Spain, ⁴Hospital La Paz-IdiPaz, Madrid, Spain, ⁵Rheumatology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁸Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain
Background/Purpose : There is a close association between serum Infliximab (Ifx) levels and the Antibodies To Infliximab (ATI) with the clinical activity in rheumatoid arthritis…
Abstract Number: 485 • 2014 ACR/ARHP Annual Meeting
Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment – a Two-Year Prospective Study in an Interdisciplinary Patient Cohort
Simon Julius Winkelmann¹, Rainald A. Zeuner¹, Dörte Schuldt¹, Johannes Bethge¹, Ulrich Mrowietz², Matthias Laudes¹, Stefan Schreiber¹ and Johann Schroeder¹, ¹1st Medical Dept, University of Kiel, Kiel, Germany, ²Dermatology, Univ Schleswig-Holstein, Kiel, Germany
Background/Purpose: TNFα-Inhibitors are the most widely used biological agents in rheumatic conditions or other chronic inflammatory diseases. Over the last ten years, the occurrence of…
Abstract Number: 75 • 2014 ACR/ARHP Annual Meeting
Robust Identification of Anti-TNF Non-Responders in RA from Blood
Ty Thomson, Reynald Lescarbeau, David Drubin, David Fryburg, David de Graaf, Renée Deehan, Daphna Laifenfeld and Aaron Van Hooser, Selventa, Cambridge, MA
Background/Purpose: The number of biologic therapies approved for use in treating rheumatoid arthritis (RA) has grown steadily over the past 15 years. While many patients…
Abstract Number: L20 • 2014 ACR/ARHP Annual Meeting
BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study
Jonathan Kay¹, Michael Wyand², Srikantiah Chandrashekara³, Davy Jacob Olakkengil⁴, Kaushik Bhojani⁵, Girish Bhatia⁶, Gaurav Rathi⁷, Suresh Maroli⁸, Elizabeth Thomson⁹, Cheryl Lassen¹⁰, Lucy Shneyer¹¹ and Arvind Chopra¹², ¹UMass Memorial Medical Center, Worcester, MA, ²Epirus Biopharmaceuticals, Boston, MA, ³Chanre Rheumatology and Immunology Centre and Research, Bangalore, India, ⁴St. John’s Medical College Hospital, Bengaluru, India, ⁵Department of Rheumatology, Fortis Hospital, Mumbai, India, ⁶Pentagon Multispeciality Clinic and Research Centre, Pune, India, ⁷Rathi Hospital, Ahmedabad, India, ⁸Reliance Life Sciences, Mumbai, India, ⁹Elizabeth Thomson LTD, London, MA, United Kingdom, ¹⁰Epirus Biopharmaceuticals, Zug, Switzerland, ¹¹Shneyer Statistics LLC, Denville, NJ, ¹²Rheumatology, Center for Rheumatic Diseases, Pune, India
Background/Purpose: Over the first 16 wks of this phase 3 double-blind (DB) comparative effectiveness clinical trial, the comparable proportion of ACR20 responders for BOW015 (a…
Abstract Number: 2766 • 2013 ACR/ARHP Annual Meeting
Improvement In Insulin Resistance Greater With The Use Of Infliximab Following Intensive Treatment Of Early Rheumatoid Arthritis
Lesley-Anne Bissell¹, Elizabeth Hensor², Sarah L. Mackie², Agata Burska³, Jackie L. Nam², Lukasz Kozera², Helen I. Keen⁴, Edith Villeneuve², Heike Eberl⁵, Helena Donica⁶, Philip G. Conaghan⁷, Jacqueline Andrews², Paul Emery⁸ and Ann W. Morgan², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, Translational Research in Immune Mediated Inflammatory Diseases, the University of Leeds, Leeds, AL, United Kingdom, ⁴Leeds, Leeds, United Kingdom, ⁵Roche Molecular Diagnostics, Burgess Hill, United Kingdom, ⁶Department of Biochemical Diagnostics, Medical University of Lublin, Lublin, Poland, ⁷NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁸Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Insulin resistance (IR), N-terminal pro-brain natriuretic peptide (NT-proBNP) and total cholesterol/high density lipoprotein cholesterol ratio (TC/HDL-C) profiles have been proposed as surrogate measures of…
Abstract Number: 2030 • 2013 ACR/ARHP Annual Meeting
Comparative Immunogenicity Of Tumor Necrosis Factor Inhibitors: Impact On Clinical Efficacy and Tolerability In The Management Of Autoimmune Diseases: A Systematic Review and Meta-Analysis
Sarah Thomas¹, Nabeel Borazan², Lewei Duan³, Nashla Barroso⁴, Sara Taroumian⁵, Banjamin Kretzmann⁶, Ricardo Bardales⁶ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, Rheumatology UCLA, Los Angeles, CA, ³David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁴Division of Rheumatology, David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, ⁵Department of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ⁶Rheumatology, University of California Los Angeles, los angeles, CA

AbstractBackground/Purpose: Tumor necrosis factor inhibitors (TNFi) are a mainstay in the treatment of rheumatoid arthritis (RA), as well as the management of spondyloarthritis (SpA) and…
Abstract Number: 1477 • 2013 ACR/ARHP Annual Meeting
A Novel Method Predicting Good Response Using Only Background Clinical Data In RA Patients Treated With Infliximab
Fumihiko Miyoshi¹, Kyoko Honne², Seiji Minota³, Masato Okada⁴, Noriyoshi Ogawa⁵ and Toshihide Mimura⁶, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Tochigi, Japan, ³Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan, ⁴Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁵Rheumatology, Hamamatsu University School of Medicine, Hamamatsu, Japan, ⁶Project Research Division, Research Center for Genomic Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Treatment using biologics is widely used for rheumatoid arthritis (RA) in these days. Prediction of the clinical response to biologics prior to the administration…
Abstract Number: 1360 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Biomarkers Involved In Periondontal Disease Including Porphyromonas Gingivalis Antibodies To Predict Response To Infliximab In Rheumatoid Arthritis Patients
Mélanie Rinaudo-Gaujous¹, Pierre Miossec², Vincent Blasco-Baque³, Philippe Gaudin⁴, Christian Genin¹, Thierry Thomas⁵, Stéphane Paul¹ and Hubert Marotte⁶, ¹Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, ²Department of Clinical Immunology and Rheumatology, Immunogenomics and inflammation research unit, Lyon, France, ³Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil, Toulouse, France, ⁴Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁵INSERM U1059 and University Hospital, Saint-Etienne, France, ⁶LBTO INSERM U1059 University Jean Monnet, Saint-Etienne, France
Background/Purpose: This study evaluates biological markers of rheumatoid arthritis (RA) severity including matrix metalloproteinase 3 (MMP-3) and Porphyromonas gingivalis (P. gingivalis) serology during infliximab therapy…
Abstract Number: 475 • 2013 ACR/ARHP Annual Meeting
Alteration Of Aortic Distensibility Within 6 Months Of Treatment In RA Patients: An Observational Comparison Of Infliximab and Synthetic Dmards
Birgul Ay¹, Dilek Keskin², Goksal Keskin³ and Ayhan Dinc⁴, ¹Internal Medicine, DYB Research and Training Hospital, Ankara, Turkey, ²Immunology, DYB Research and Training Hospital, Ankara, Turkey, ³Internal Medicine and Clinical Immunology, DYB Research and Training Hospital, Ankara, Turkey, ⁴Rheumatology, Patio Clinic, Ankara, Turkey
Background/Purpose: The proximal aorta accounts for most of the global arterial stiffening and subsequent complications. Aortic stiffness can be demonstrated by changes in aortic dimensions…
Abstract Number: L1 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of CT-P13 (Infliximab biosimilar) over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13
Dae-Hyun Yoo¹, Nenad Prodanovic², Janusz Jaworski³, Pedro Miranda⁴, Edgar B. Ramiterre⁵, Allan Lanzon⁶, Asta Baranauskaite⁷, Piotr Wiland⁸, Carlos Abud-Mendoza⁹, Boycho Oparanov¹⁰, Svitlana Smiyan¹¹, YoungKi Son¹², Won Park¹³ and Ulf Müller-Ladner¹⁴, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Clinical Center Banja Luka, Banja Luka, Bosnia, ³Reumatika Centrum Reumatologi, Warszawa, Poland, ⁴Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ⁵Brokenshire Memorial Hospital, Davao City, Philippines, ⁶Mary Mediatrix Medical Center, Batangas, Philippines, ⁷Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania, ⁸Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁹Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosyi, Mexico, ¹⁰Military Medical Academy, Sofia, Bulgaria, ¹¹Municipal Institution of Ternopil Regional Council "Ternopil University Hospital", Ternopil, Ukraine, ¹²CELLTRION, Incheon, South Korea, ¹³Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ¹⁴Internal Medicine and Rheumatology, Justus-Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany
Background/Purpose: CT-P13 is a biosimilar of infliximab (INX), approved by the European Medicines Agency. The objective of this open-label Phase 3 extension study was to…
Abstract Number: 493 • 2012 ACR/ARHP Annual Meeting
Effect of Infliximab On Employment Status in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis
W. Bensen¹, J. Carter Thorne², Saeed A. Shaikh³, Maqbool K. Sheriff⁴, Susan M. Otawa⁵, Allen J. Lehman⁵ and Hayssam Khalil⁶, ¹St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, McMaster University, St Catharines, ON, Canada, ⁴Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁶Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with significant functional impairment and work disability. In the absence of treatment, approximately 80% of…
Abstract Number: 478 • 2012 ACR/ARHP Annual Meeting
Body Mass Index Negatively Influences the Response to Infliximab in Rheumatoid Arthritis
Sébastien Ottaviani¹, Anais Gardette², Emilie Quintin², Karen Dawidowicz², Ghislaine Gill², Elisabeth Palazzo³, Olivier Meyer⁴ and Philippe Dieude⁵, ¹Service de Rhumatologie, Hôpital Bichat, APHP, APHP, Paris, France, ²Rheumatology, APHP, Hopital Bichat, Paris, France, ³Hopital Bichat, Paris, France, ⁴Rheumatology, Hopital Bichat, Paris, France, ⁵Rheumatology, Rheumatology departement & INSERM U699, Paris Diderot university, APHP, Bichat hospital, Paris, France
Background/Purpose: The excess of adipose tissue in obese individuals may have immunomodulating properties and pharmacokinetics consequences. Adipose tissue is potentially involved in the regulation of…
Abstract Number: 445 • 2012 ACR/ARHP Annual Meeting
Combination of Intra-Articular Steroid Injection and Infliximab More Effective Than Infliximab in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, x Ray Reader Blinded Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Hiroyuki Ohta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, recent publications described rapid radiographic progression (RRP) existed despite initial biologics and methotrexate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].